Clinical Trial: CAR-T Cell Therapy for ALL

U.S., July 11 -- ClinicalTrials.gov registry received information related to the study (NCT07695012) titled 'CAR-T Cell Therapy for ALL' on June 27.

Brief Summary: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children and the second most frequent acute leukemia in adults. B-cell ALL constitutes approximately 85% of all ALL diagnoses. In Pakistan, ALL represents the most prevalent haematological malignancy presenting to tertiary centres, with AFBMTC receiving the largest national referral volume for haematological malignancies and transplantation.

First-line combination chemotherapy achieves complete remission (CR) in >95% of paediatric patients; however, 15-20% relapse. Outcomes following first relapse are substanti...